Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siremadlin +/- DLI for High-Risk AML Post-Transplant
NCT05447663Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of siremadlin in acute myeloid leukemia (AML), sponsored by Novartis. Started Feb 2023; status: terminated.
02
Drugs
siremadlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05447663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05447663.